Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK

Current Medical Research and Opinion

Volumn 23, Issue 12, 2007, Pages 3069-3078

  Jansen, Jeroen P ^a   Pellissier, James ^b   Choy, Ernest H ^c   Ostor, Andrew ^d   Nash, Julian T ^e   Bacon, Paul ^f   Hunsche, Elke ^b  

^a MAPI GROUP   (Netherlands)

^b MERCK RESEARCH LABORATORIES   (United States)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e BARNET HOSPITAL   (United Kingdom)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Ankylosing spondylitis; Cost effectiveness; Cox 2 inhibitors; Economics; Etoricoxib; Non selective NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABSENTEEISM; ADVERSE OUTCOME; ANALYTIC METHOD; ANKYLOSING SPONDYLITIS; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG USE; GASTROINTESTINAL HEMORRHAGE; HEALTH ECONOMICS; HEALTH SERVICE; HUMAN; OUTCOME ASSESSMENT; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SHORT FORM 36; TREATMENT DURATION; UNITED KINGDOM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COST-BENEFIT ANALYSIS; CYCLOOXYGENASE INHIBITORS; DRUG COSTS; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PYRIDINES; SPONDYLITIS, ANKYLOSING; SULFONES; TREATMENT OUTCOME;

EID: 37749050376     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X242575     Document Type: Article

References (52)

1. Gran JT, Husby G. Clinical, epidemiologic, and therapeutic aspects of ankylosing spondylitis. Curr Opin Rheumatol 1998;10:292-8
2. Boonen A, van der Heijde D, Landewe R. Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Ann Rheum Dis 2003;62:732-40
3. Kobelt G, Andlin-Sobocki P, Brophy S, et al. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Rheumatology 2004;43:1158-66
4. Sieper J, Braun J. New treatment options in ankylosing spondylitis: a role for anti-TNFα therapy. Ann Rheum Dis 2001;60:iii58-61
5. Braun J, Pham T, Sieper J, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-24
6. Zochling J, van der Heijde D, Dougados M, et al. Current evidence for the management of ankylosing spondylitis a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006;65:423-32
7. Keat A. BSR guideline for prescribing TNF alpha blockers in adults with ankylosing spondylitis. The British Society for Rheumatology, 2004
8. Rostom A, Dubé C, Jolicoeur E, et al. Gastroduodenal ulcers associated with the use of non-steroidal anti-inflammatory drugs: a systematic review of preventative pharmacological interventions. Ottawa: Canadian Coordinating Office for Health Technology Assessment, Technology overview no. 12, 2004
9. Jenkins JK, Seligman PJ. FDA decision memo - analysis and recommendations for agency action - COX-2 selective and non-selective NSAIDs. 2005. Available from http://www.fda.gov/cder/drug/infopage/cox2/NSAIDdecisionMemo.pdf [Last accessed 28 July 2006]
10. van der Heijde D, Baraf HS, Ramos-Remus C, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005;52:1205-15
11. Ramey DR, Watson JD, Yu CB, et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin 2005;21:715-22
12. Laine L, Reicin AS, Yu Q, et al. COX-2 selective inhibitors rofecoxib and etoricoxib decrease serious lower gastrointestinal clinical events compared to non-selective NSAIDs: a meta-analysis. The 11th Asia Pacific League of Associations for Rheumatology Congress. Korea, Jeju, September 11-15, 2004, pp. 85-6
13. Curtis SP, Mukhopadhyay S, Ramey D, et al. Cardiovascular safety summary associated with the etoricoxib development program. Arthritis Rheum 2003;48:S35-750
14. Moore RA, Phillips CJP, Hunsche E, et al. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK. Pharmacoeconomics 2004;22:643-60
15. MediPlus IMS UK, 2003
16. Bird HA, Le Gallez P, Astbury C. A parallel group comparison of tenoxicam and piroxicam in patients with ankylosing spondylitis. Pharmatherapeutica 1986;4:457-62
17. Batlle-Gualda E, Figueroa M, Ivorra J, et al. The efficacy and tolerability of aceclofenac in the treatment of patients with ankylosing spondylitis: a multicenter controlled clinical trial. Aceclofenac Indomethacin Study Group. J Rheumatol 1996;23:1200-6
18. Khan MA. A double blind comparison of diclofenac and indomethacin in the treatment of ankylosing spondylitis. J Rheumatol 1987;14:118-23
19. Santo JE, Queiroz MV. Oxaprozin versus diclofenac sodium in the treatment of ankylosing spondylitis. J Int Med Res 1988;16:150-6
20. Schwarzer AC, Cohen M, Arnold MH, et al. Tenoxicam compared with diclofenac in patients with ankylosing spondylitis. Curr Med Res Opin 1990;11:648-53
21. McKenna F. Efficacy of diclofenac/misoprostol vs. diclofenac in the treatment of ankylosing spondylitis. Drugs 1993;45 (Suppl 1):24-30
22. Villa Alcazar LF, de Buergo M, Rico LH, et al. Aceclofenac is as safe and effective as tenoxicam in the treatment of ankylosing spondylitis: a 3 month multicenter comparative trial. Spanish Study Group on Aceclofenac in Ankylosing Spondylitis. J Rheumatol 1996;23:1194-9
23. Tramer MR, Moore RA, Reynolds DJ, et al. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 2000;85:169-82
24. Moore RA, Phillips CJ, Pellissier JM, et al. Health economic comparisons of rofecoxib versus conventional nonsteroidal anti-inflammatory drugs for osteoarthritis in the United Kingdom. Journal of Medical Economics 2001;4:1-17
25. Cullen D, Bardhan KD, Eisner M, et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther 1998;12:135-40
26. Ariza-Ariza R, Hernandez-Cruz B, Navarro-Sarabia F. Physical function and health-related quality of life of Spanish patients with ankylosing spondylitis. Arthritis Rheum 2003;49:483-7
27. Ware JE. SF-36: the SF-36 community. Available from http://www.sf-36.org/ tools/sf36.shtml#CONSTRUCT [Last accessed 10 May 2004]
28. Nichol MB, Sengupta N, Globe DR. Evaluating quality-adjusted life years: estimation of the health utility index (HUI2) from the SF-36. Med Decis Making 2001;21:105-12
29. Marzo-Ortega H, McGonagle D, O'Connor P, et al. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 2001;44:2112-7
30. Boonen A, Van Der Heijde, Landewe R, et al. Work status and productivity costs due to ankylosing spondylitis. A comparison among three European countries. Ann Rheum Dis 2002;61:429-37
31. Monthly digest of statistics. December 2004, No 708. UK Office for National Statistics: Palgrave Macmillan
32. Government Actuary's Department (GAD) interim life tables 1999-2001, UK. Available from http://www.gad.gov.uk/Life_Tables/Interim_life_tables.htm [Last accessed 10 Mar 2005]
33. Robertson LP, Davis MJ. A longitudinal study of disease activity and functional status in a hospital cohort of patients with ankylosing spondylitis. Rheumatology 2004;43:1565-8
34. Briggs A, Sculpher M, Claxton K, editors. Making decision models probabilistic. Decision modelling for health economic evaluation, pp 77-120. Oxford: Oxford University Press, 2006
35. Moore RA, Derry S, Phillips CJ, et al. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord 2006;7:79
36. Curtis SP, Ng J, Yu Q, et al. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. Clin Ther 2004;26:70-83
37. Boonen A, Chorus A, Miedema H, et al. Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 2001;60:353-8
38. Maetzel A, Krahn M, Naglie G. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum 2003;49:283-92
39. Bloom BS. Direct medical costs of disease and gastrointestinal side effects during treatment of arthritis. Am J Med 1988;84:315-22
40. Maetzel A, Bosi Ferraz M, Bombardier C. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs. Arth Rheum 1998;41:16-25
41. Knill-Jones R, Drummond M, Kohli H, et al. Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugs. Postgrad Med J 1990;66:639-46
42. Singh G, Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective - 1997. Arthritis, rheumatism, and aging medical information system. J Rheum 1998;51:8-16
43. de Pouvourville G. The economic consequences of NSAID-induced gastropathy: The French context. Scand J Rheumatol Suppl 1992;96:49-53
44. Jönsson B, Haglund U. Cost-effectiveness of misoprostol in Sweden. Int J Tech Assess Health Care 1992;8:234-44
45. Gabriel SE, Matteson EL. Economic and quality of life impact of NSAIDs in rheumatoid arthritis: a conceptual framework and selected literature review. Pharmacoeconomics 1995;8:479-90
46. Smalley WE, Griffin MR, Fought RL, et al. Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. J Gen Intern Med 1996;11:461-9
47. Edelson JT, Tosteson ANA, Sax P. Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal tract bleeding. JAMA 1990;264:41-7
48. Gabriel SE, Campion ME, O'Fallon WM. Patient preferences for nonsteroidal antiinflammatory drug-related gastrointestinal complications and their prophylaxis. J Rheum 1993;20:258-61
49. Gabriel SE, Jaakkimainen RL, Bombardier C. The cost-effectiveness of misoprostol for non-steroidal anti-inflammatory drug-associated adverse gastrointestinal events. Arth Rheum 1993;36:447-59
50. Johnson RE, Hornbrook MC, Hooker RS, et al. Analysis of the costs of NSAID-associated gastropathy. Experience in a US health maintenance organization. Pharmacoeconomics 1997;12:76-88
51. Kong SX, Hatoum HT, Zhao SZ, et al. Prevalence and cost of hospitalization for gastrointestinal complications related to peptic ulcers with bleeding or perforation: comparison of two national databases. Am J Manag Care 1998;4:399-409
52. Curtis L, Netten A. Unit costs of health and social care 2004. Personal Social Services Research Unit, University of Kent, Canterbury, UK, 2004